Tavares et al. [123] pointed that mercaptoacetamide-based histone deacetylase inhibitors have some anti-tumor effects (e.g., prostate cancer) and might be considered as a potential therapeutic target for neurodegenerative disorder’s such as AD due to promoting dendritic spine density, leading to decrease in human Aß40, Aß42, and phosphorylated tau (Thr181) levels, and impacts Aß levels by downregulating Aß-production pathways while upregulating Aß clearance pathways. Here, MAPT is linked to Alzheimer disease.